Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatments

Find Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatments

Generic Name

Pegcetacoplan

Brand Names

Empaveli, Syfovre

FDA approval date: May 14, 2021

Classification: Complement Inhibitor

Form: Injection

What is Empaveli (Pegcetacoplan)?

EMPAVELI is a complement inhibitor indicated: for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled

Enrollment Status: Recruiting

Publish Date: April 03, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

Enrollment Status: Recruiting

Publish Date: March 30, 2026

Intervention Type: Drug, Other

Study Phase: Phase 2

Summary: A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

Who is this study for: Patients with Adenocarcinoma

Enrollment Status: Recruiting

Publish Date: March 23, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Bevacizumab, Pegcetacoplan, Pembrolizumab

Study Phase: Phase 2

Summary: This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion...

View All Clinical Trials